In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent

Nuclear Medicine and Biology

Volumn 24, Issue 7, 1997, Pages 639-647

  Reist, Craig J ^a   Batra, Surinder K ^a   Pegram, Charles N ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chimeric; EGFRvIII; Internalization; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

CHIMERIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DRUG DISTRIBUTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; RADIOIMMUNOTHERAPY; RADIOIODINATION; RECEPTOR AFFINITY; TISSUE DISTRIBUTION; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; DNA; GENE LIBRARY; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MOLECULAR SEQUENCE DATA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030818101     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00080-2     Document Type: Article

References (32)

1. Batra S. K., Castelino-Prabhu S., Wikstrand C. J., Zhu X., Humphrey P. A., Friedman H. S. et al. (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6, 1251-1259.
2. Batra S. K., Niswonger M. L., Wikstrand C. J., Pegram C. N., Zalutsky M. R., Morrison S. L. et al. (1994) Mouse/human chimeric Mel-14 antibody: Genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma 13, 87-97.
3. Batra S. K., Metzgar R. S. and Hollingsworth M. A. (1991) Isolation and characterization of a complementary DNA (PD-1) differentially expressed by human pancreatic ductal cell tumors. Cell Growth Differ. 2, 385-390.
4. Batra S. K., Metzgar R. S. and Hollingsworth M. A. (1991) Molecular cloning and sequence analysis of the human ribosomal protein S16. J Biol Chem. 266, 6830-6833.
5. 2 fragments of IgG1, IgG2, and IgG4 sub-class in vivo. Int. J. Cancer 50, 416-422.
6. 131I-labeled monoclonal antibody CC49. Cancer Res. 55, 5881s-5887s.
7. Colcher D., Milenic D., Roselli M., Raubitschek A., Yarranton G., King D. et al. (1989) Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 49, 1738-1745.
8. Geissler F., Anderson S. K., Venkatesan P. and Press O. (1992) Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 52, 2907-2915.
9. Gillies S. D. and Wesolowski J. S. (1990) Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum. Antibodies Hybridomas 1, 47-54.
10. Goodman G. E., Hellstrom I., Yelton D. E., Murray J. L., O'Hara S., Meaker, E. et al. (1993) Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother. 36, 267-273.
11. He X., Archer G. E., Wikstrand C. J., Morrison S. L., Zalutsky M. R., Bigner D. D. et al. (1994) Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol. 52, 127-137.
12. Lindmo T., Boven E., Cuttitta F., Fedorko J. and Bunn P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89.
13. McCloskey N., Turner M. W., Steffner P., Owens R. and Goldblatt D. (1996) Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. Immunology 88, 169-173.
14. Molthoff C. F., Buist M. R., Kenemans P., Pinedo H. M. and Boven E. (1992) Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J. Nucl. Med. 33, 2000-2005.
15. Morrison S. L., Johnson M. J., Herzenberg L. A. and Oi V. T. (1984) Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851-6855.
16. Morrison S. L. and Oi V. T. (1984) Transfer and expression of immunoglobulin genes. Annu. Rev. Immunol. 2, 239-256.
17. Moscatello D. K., Holgado-Madruga M., Godwin A. K., Ramirez G., Gunn G., Zoltick P. W. et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55, 5536-5539.
18. Nishikawa R., Ji X. D., Harmon R. C., Lazar C. S., Gill G. N., Cavenee W. K. et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U S A 91, 7727-7231.
19. Novak-Hofer I., Amstutz H. P., Morgenthaler J. J. and Schubiger P. A. (1994) Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells. Int. J. Cancer 57, 427-432.
20. Novak-Hofer I., Amstutz H. P., Haldemann A., Blaser K., Morgenthaler J. J., Blauenstein P. et al. (1992) Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7. J. Nucl. Med. 33, 231-236.
21. Press O. W., DeSantes K., Anderson S. K. and Geissler F. (1990) Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. Cancer Res. 50, 1243-1250.
22. Reist C. J., Archer G. E., Wikstrand C. J., Bigner D. D. and Zalutsky M. R. (1997) Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 57, 1510-1515.
23. Reist C. J., Garg P. K., Alston K. L., Bigner D. D. and Zalutsky M. R. (1996) Radioiodinated of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 56, 4970-4977.
24. Reist C. J., Archer G. E., Kurpad S. N., Wikstrand C. J., Vaidyanathan G., Willingham M. C. et al. (1995) Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 55, 4375-4382.
25. Schlom J., Molinolo A., Simpson J. F., Siler K., Roselli M., Hinkle G. et al. (1990) Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J. Natl. Cancer Inst. 82, 763-771.
26. Shih L. B., Lu H. H., Xuan H. and Goldenberg D. M. (1994) Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int. J. Cancer 56, 538-545.
27. Shin S. U. (1991) Chimeric antibody: Potential applications for drug delivery and immunotherapy. Biotherapy 3, 43-53.
28. Sun L. K., Curtis P., Rakowicz-Szulczynska E., Ghrayeb J., Chang N., Morrison S. L. et al. (1987) Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc. Natl. Acad. Sci. U S A 84, 214-218.
29. Sun L.-Q., Vogel C.-A., Mirimanoff R.-O., Coucke P., Slosman D. O., Mach J.-P. et al. (1997) Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res. 57, 1312-1319.
30. Tjandra J. J., Ramadi L. and McKenzie I. F. (1990) Development of human anti-murine antibody (HAMA) response in patients. Immunol. Cell Biol. 68, 367-376.
31. Wikstrand C. J., Hale L. P., Batra S. K., Hill M. L., Humphrey P. A., Kurpad S. et al. (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148.
32. Zalutsky M. R., Archer G. E., Garg P. K., Batra S. K. and Bigner D. D. (1996) Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent. Nucl. Med. Biol. 23, 449-458.